Kaynak: MarketBeat
Haber Ajansı
Hisse Senedi
Orta Önem
Precigen Q2 Earnings Call Highlights
Precigen NASDAQ: PGEN reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy's August 2025 FDA approval for adults with recurrent respiratory papillomatosis, or RRP.
İlgili Semboller
1
P
PGEN
PGEN
Kaynak: MarketBeat
Kaynağı Ziyaret Et